Fulgent Genetics (FLGT) Net Cash Flow (2015 - 2026)

Fulgent Genetics has disclosed Net Cash Flow across 12 years of filings, most recently posting -$26.8 million for Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$26.8 million, down 320.99% year-over-year; the trailing twelve-month figure through Mar 2026 was -$44.0 million (down 445.91% YoY), and the FY2025 annual result was -$5.1 million, up 88.0% from the prior year.
• Net Cash Flow came in at -$26.8 million for Q1 2026 at Fulgent Genetics, up from -$67.5 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $188.2 million in Q1 2022 to a low of -$213.7 million in Q2 2022.
• The 5-year median for Net Cash Flow is -$2.8 million (2024), against an average of -$8.3 million.
• Peak annual rise in Net Cash Flow reached 519.49% in 2025, while the deepest fall reached 2342.95% in 2025.
• Fulgent Genetics' Net Cash Flow stood at -$89.0 million in 2022, then jumped by 114.89% to $13.3 million in 2023, then plunged by 120.86% to -$2.8 million in 2024, then sank by 2342.95% to -$67.5 million in 2025, then surged by 60.31% to -$26.8 million in 2026.
• The last three Net Cash Flow figures came in at -$26.8 million (Q1 2026), -$67.5 million (Q4 2025), and $29.7 million (Q3 2025), per Business Quant data.